TESARO (TSRO) Phase 3 Niraparib Results a 'Grand Slam' - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Tesaro (TSRO) Valuation Range Lifted to $122-$132 at Wells Fargo
June 29, 2016 9:48 AM EDTWells Fargo analyst Jim Birchenough raised his valuation range on Outperform-rated Tesaro (NASDAQ: TSRO) to $122-$132 from $88-495 following today's positive NOVA results.
For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.
Shares of Tesaro closed at $37.21 yesterday.
... MoreCredit Suisse Sees $157B of FCF Through 2019 Available for M&A in Biotech/Pharma Sector
June 29, 2016 7:56 AM EDTAnalysts at Credit Suisse evaluated potential M&A in the biotech sector beyond Medivation (NASDAQ: MDVN), which in addition to a hostile bid from Sanofi (NYSE: SNY) has been looked at by multiple firms.
Analysts led by Vamil Divan said... More
TESARO (TSRO) Nearly Doubles as Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint
June 29, 2016 7:47 AM EDTTESARO (NASDAQ: TSRO) is surging 88% in pre-open trade after the company announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary... More
TESARO (TSRO) Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint
June 29, 2016 7:02 AM EDTTESARO, Inc. (NASDAQ: TSRO) announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival (PFS). This trial demonstrated that niraparib significantly prolonged PFS compared to control among patients who are germline BRCA mutation (gBRCAmut) carriers, among patients who are not germline BRCA mutation (non-gBRCAmut) carriers but who have homologous recombination deficient (HRD) tumors as determined by the Myriad myChoice® HRD test, and overall in patients who are not germline BRCA mutation carriers.
We are extremely grateful to the patients, caregivers, and investigators who participated in... More
